Subscription in IQ-AI Ltd Placing

18 March 2025

Braveheart Investment Group plc

(the "Company")

Subscription in IQ-AI Ltd Placing

Braveheart Investment Group plc (AIM: BRH) announces the participation in IQ-AI Ltd's ("IQ-AI") placing to raise £250,000 (the "Placing") via the issuance of 25,000,000 new ordinary shares (the "Placing Shares") at a price of £0.01 per share (the "Issue Price"). The Company, an existing shareholder in IQ-AI, has subscribed for 7,000,000 Placing Shares for a consideration of £70,000. On admission of the Placing Shares, the Company will hold 72,415,862 ordinary shares in IQ-AI which represents 29.35% of the issued share capital of IQ-AI as enlarged by the Placing.

IQ-AI, the parent company of Wisconsin-based Imaging Biometrics, LLC (IB), is focused on delivering quantitative imaging platforms and therapeutics that transform how clinicians diagnose and treat patients more efficiently and effectively. IQ-AI's ordinary shares are listed on the main market of the London Stock Exchange.

In the year ended 31 December 2023, IQ-AI made a loss before tax of approximately £0.62 million on revenue of approximately £0.6 million and as at that date had net assets of approximately £0.09 million. As at 30 June 2024, IQ-AI had net assets of approximately £0.43 million.

The Board continues to seek investment opportunities, both within its existing portfolio and from outside. The Braveheart Board considers this investment to be a strategic investment and thus an important addition to the Group's portfolio.

For further information: